Clinical Trials Browser

Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07517705 2026-04-08

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Phase NA Not yet recruiting

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 2 Not yet recruiting

69 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07247201 2026-03-30

AlloNK1

Phase 1/2 Not yet recruiting

31 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07483476 2026-03-19

CIRCALL

Not yet recruiting

205 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

300 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

330 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Phase NA Not yet recruiting

100 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Not yet recruiting

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Phase NA Not yet recruiting

276 enrolled

Recurrence, Neoplasm, Residual

Clinical Trials

RT4

Motixafortide for MRD Sensitization in AML

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

DEL-MRD-CHID

AlloNK1

CIRCALL

TRACE-BTC

LAL-2025

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC